Astrazeneca plc - ADR
AZN
Market Cap$211.95B
Close$
Earnings Call Q4 2023
February 8, 2024 - AI Summary
AstraZeneca achieved its goal of reaching $45 billion in sales by 2023, exceeding expectations.
The company expects low double-digit to low teens percentage growth in total revenue for 2024, driven by strong product sales and collaboration revenues.
Product sales are expected to continue growing strongly, with momentum from current products and new launches.
Exclusive for Stockcircle Pro members
Sign up
$81.73
15.4% upside
Current Fair Value
15.4% upsideUndervalued by 15.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $211.95 Billion |
|---|---|
| Enterprise Value | $234.61 Billion |
| Dividend Yield | $1.436 (2.1%) |
| Earnings per Share | $1.91 |
| Beta | 0.55 |
| Outstanding Shares | 3,100,442,576 |
| Avg 30 Day Volume | 5,344,684 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 35.59 |
|---|---|
| PEG | 523.95 |
| Price to Sales | 5.06 |
| Price to Book Ratio | 5.9 |
| Enterprise Value to Revenue | 5.12 |
| Enterprise Value to EBIT | 33.77 |
| Enterprise Value to Net Income | 39 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.73 |
Revenue Sources
No data
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...